Research & Development
Publications & Presentations
Disclaimer
Etripamil is an investigational new drug which is not approved for commercial distribution in the United States. The publications in this section are for educational purposes to discuss clinical data relating to the investigational new drug. Etripamil has not been shown to be safe and effective for FDA approval purposes.
Phase 2
Randomized Controlled Trial
A Multicenter, Phase 2, Randomized, Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients with Symptomatic Atrial Fibrillation (ReVeRA-201)
Circulation: Arrhythmia and Electrophysiology (Nov 2023)
Etripamil Use in Atrial Fibrillation with Rapid Ventricular Rate.
Western Atrial Fibrillation (WAFib) Symposium. (Feb 2024)
Concomitant Antiarrhythmic Use Among Patients Who Received Etripamil for Atrial Fibrillation with Rapid Ventricular Rate.
Western Atrial Fibrillation (WAFib) Symposium (Feb 2024)
Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients with Atrial Fibrillation: Phase 2 ReVeRA-201.
Cardiovascular Clinical Trialists. (Nov 2023)
Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients with Atrial Fibrillation: Phase 2 ReVeRa-201
American Heart Association (Nov 2023)
Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Presentation
Heart Rhythm Society (May 2023)
Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Poster
Heart Rhythm Society (May 2023)
.png){kind=small}